26 results on '"Geater, Sarayut L"'
Search Results
2. PAP Treatment of Obstructive Sleep Apnea-Hypopnea in Hypertensive Disorders of Pregnancy: A Pilot Randomized Proof-of-the-Concept Study
3. Exploring previously used thresholds for computed tomography‐defined low skeletal muscle mass in predicting functional limitations among lung cancer patients.
4. Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials
5. Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
6. Occupational Tasks Influencing Lung Function and Respiratory Symptoms Among Charcoal-Production Workers: A Time-Series Study
7. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
8. Positive Airway Pressure Treatment of Obstructive Sleep Apnea–Hypopnea in Hypertensive Disorders of Pregnancy: A Pilot Randomized Proof-of-Concept Clinical Trial.
9. Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non–small-cell Lung Cancer
10. Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)
11. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
12. Catastrophic and Socioeconomic Disparities Across Different Payment Schemes in Lung Cancer Treatment: A Cross-Sectional Single-Centre Analysis from Thailand
13. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
14. The hidden financial catastrophe of chronic kidney disease under universal coverage and Thai “Peritoneal Dialysis First Policy”
15. Afatinib in Locally Advanced/Metastatic NSCLC Harboring Common EGFR Mutations, After Chemotherapy: a Phase IV Study
16. Procedure-related tumour seeding in lung cancer with malignant pleural effusion: Radiological features and outcomes
17. Impact of Dose Adjustment on Afatinib Safety and Efficacy in EGFR Mutation-Positive NSCLC: Post-Hoc Analyses of LUX-Lung 3/6: Track: Advanced NSCLC
18. Afatinib Versus Chemotherapy for EGFR Mutation-Positive NSCLC Patients Aged >=65 Years : Subgroup Analysis of LUX-Lung 3/6: P1.33: Track: Advanced NSCLC
19. P1.33: Afatinib versus chemotherapy for EGFR mutation-positive NSCLC patients aged ≥65 years: Subgroup Analysis of LUX-Lung 3/6: Track: Advanced NSCLC
20. P1.45: Impact of Dose Adjustment on Afatinib Safety and Efficacy in EGFR Mutation-Positive NSCLC: Post-Hoc Analyses of LUX-Lung 3/6
21. P1.45: Impact of Dose Adjustment on Afatinib Safety and Efficacy in EGFR Mutation-Positive NSCLC: Post-Hoc Analyses of LUX-Lung 3/6
22. P1.33: Afatinib Versus Chemotherapy for EGFR Mutation-Positive NSCLC Patients Aged ≥65 Years: Subgroup Analysis of LUX-Lung 3/6
23. Afatinib in locally advanced/metastatic NSCLC harboring common EGFRmutations, after chemotherapy: a Phase IV study
24. Impact of Calcium Phosphate Product on Acute Kidney Injury and Mortality: A Retrospective Cohort Study.
25. Transthoracic imaging-guided biopsy of lung lesions: evaluation of benign non-specific pathologic diagnoses.
26. Outcome of ultrasound-guided small-bore catheter drainage in exudative pleural effusions.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.